NCT06579014

Brief Summary

The goal of this observational study is knowledge of Prevalence of throid abnormalities in patients with acute coronary syndrome And prognostic effects of thyroid abnormalities in patients with acute coronary syndrome as early detection and management of thyroid abnormalities can improve clinical outcomes.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
129

participants targeted

Target at P50-P75 for all trials

Timeline
6mo left

Started Sep 2024

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress78%
Sep 2024Nov 2026

First Submitted

Initial submission to the registry

August 27, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 30, 2024

Completed
2 days until next milestone

Study Start

First participant enrolled

September 1, 2024

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Last Updated

September 19, 2024

Status Verified

September 1, 2024

Enrollment Period

2.1 years

First QC Date

August 27, 2024

Last Update Submit

September 5, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence of thyroid abnormalities in patients with acute coronary syndrome .

    Prevalence of thyroid abnormalities in patients with acute coronary syndrome .

    1/9/2024-1/10/2025

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with ACS and thyroid abnormalities. patients with ACS and euthyroid.

You may qualify if:

  • Patients with ACS: (STEMI\_NSTEMI)

You may not qualify if:

  • patients with cardiogenic shock. 2- patients with other endocrinal diseases. 3- patients on dialysis. 4-patients with Acute malignancy. 5-patient with thyroid diseases on treatment. 6- patients with liver diseases. 7-patients with Any autoimmune diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Rowyda Elsayed, Dr

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 27, 2024

First Posted

August 30, 2024

Study Start

September 1, 2024

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

November 1, 2026

Last Updated

September 19, 2024

Record last verified: 2024-09